Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street

This article was originally published in RPM Report

Executive Summary

Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.

You may also be interested in...



The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure

The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.

Capping Off The Rebate Debate: Will 2019 Price Push End With Co-Pay Cap?

The pharmaceutical industry and its strongest critics have long agreed on one thing: Medicare Part D would be improved if there was a cap on spending by beneficiaries. Now, there is an unlikely path that may make it surprisingly easy to get it done.

Trump’s Election Could Bring ‘Best Of Times’ For Pharma

Obama administration wasn’t bad but had ‘less than thrilling moments,’ BIO exec says; former FDA Commissioner says leadership, not scientific, skill is key attribute for next agency chief.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS079779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel